Glenda V. Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Glenda V. Roberts has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Patrick O. Gee
Advocate
4 shared publications - Ian H. de Boer
University of Washington
3 shared publications - Katherine R. Tuttle
Providence Inland Northwest Health, University of Washington School of Medicine, Spokane, WA
3 shared publications - Ana Smith Iltis
Wake Forest University
2 shared publications - Jonathan Himmelfarb
Icahn School of Medicine at Mount Sinai, New York, New York
2 shared publications - Krista L. Lentine
SSM Health Saint Louis University Hospital, United States
2 shared publications
Latest Publications
- 28 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1608-1610
In Memoriam of Dr. Murray I. Sheldon
An abstract is unavailable. This article is available as a PDF only.
- 28 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1608-1610
In Memoriam of Dr. Murray I. Sheldon
An abstract is unavailable. This article is available as a PDF only.
- 13 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1647-1648
Advancing Health Equity in Kidney Disease through Sustainable Policy and Community Partnership
- 13 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1647-1648
Advancing Health Equity in Kidney Disease through Sustainable Policy and Community Partnership
- Top Cited Papers
- 1 May 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (5) , 705-713
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy. The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics. Latest searches of the English-language literature were done in July 2023. Final modification of the guideline was informed by a public review process during summer of 2023 involving registered stakeholders. The full guideline included 28 recommendations and 141 practice points. This synopsis focuses on the recommendations that have the greatest evidence. Practice points reflect the expert opinion of the group where evidence is not that strong. Recommendations include greater emphasis on cystatin C for assessment of glomerular filtration rate, point-of-care testing in remote areas, a shift to an individualized risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years and CKD. Together the recommendations and practice points provide guidance for how to evaluate and manage persons with CKD.
- 1 May 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (5) , 705-713
Top Cited PapersEvaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy. The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics. Latest searches of the English-language literature were done in July 2023. Final modification of the guideline was informed by a public review process during summer of 2023 involving registered stakeholders. The full guideline included 28 recommendations and 141 practice points. This synopsis focuses on the recommendations that have the greatest evidence. Practice points reflect the expert opinion of the group where evidence is not that strong. Recommendations include greater emphasis on cystatin C for assessment of glomerular filtration rate, point-of-care testing in remote areas, a shift to an individualized risk-based approach to predict kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years and CKD. Together the recommendations and practice points provide guidance for how to evaluate and manage persons with CKD.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 26 December 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (4) , 730-733
Practical Considerations for Sharing Race-Based Genetic Research Findings
An abstract is unavailable. This article is available as a PDF only.
- 26 December 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (4) , 730-733
Practical Considerations for Sharing Race-Based Genetic Research Findings
An abstract is unavailable. This article is available as a PDF only.
- 12 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (10) , 1442-1445
Patient, Nurse, and Physician Perspectives on Personalized, Incremental Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 12 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (10) , 1442-1445
Patient, Nurse, and Physician Perspectives on Personalized, Incremental Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 23 October 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (2) , 202-212
Participant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project
Background: Kidney biopsies are procedures commonly performed in clinical nephrology and are increasingly used in research. In this study, we aimed to evaluate the experiences of participants who underwent research kidney biopsies in the Kidney Precision Medicine Project (KPMP). Methods: KPMP research participants with AKI or CKD were enrolled at nine recruitment sites in the United States between September 2019 and January 2023. At 28 days postbiopsy, participants were invited to complete a survey to share their experiences, including motivation to participate in research, comprehension of informed consent, pain and anxiety during and after the biopsy procedure, overall satisfaction with KPMP participation, and effect of the study on their lives. The survey was developed in collaboration with the KPMP Community Engagement Committee and the Institute of Translational Health Sciences at the University of Washington. Results: One hundred and eleven participants completed the survey, 23 enrolled for AKI and 88 for CKD. The median age was 61 (interquartile range [IQR], 48–67) years, 43% were women, 28% were Black, and 18% were of Hispanic ethnicity. Survey respondents most commonly joined KPMP to help future patients (59%). The consent form was understood by 99%, and 97% recognized their important role in this study. Pain during the biopsy was reported by 50%, at a median level of 1 (IQR, 0–3) on a 0–10 scale. Anxiety during the biopsy was described by 64% at a median level of 3 (IQR, 1–5) on a 0–10 scale. More than half conveyed that KPMP participation had an effect on their diet, physical activity, and how they think about kidney disease. Conclusions: KPMP survey respondents were most commonly motivated to participate in research protocol kidney biopsies by altruism, with excellent understanding of the informed consent process. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_CJN0000000000000334.mp3 This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_Spanish_CJN00000000.mp3
- 23 October 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (2) , 202-212
Open AccessParticipant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project
Background: Kidney biopsies are procedures commonly performed in clinical nephrology and are increasingly used in research. In this study, we aimed to evaluate the experiences of participants who underwent research kidney biopsies in the Kidney Precision Medicine Project (KPMP). Methods: KPMP research participants with AKI or CKD were enrolled at nine recruitment sites in the United States between September 2019 and January 2023. At 28 days postbiopsy, participants were invited to complete a survey to share their experiences, including motivation to participate in research, comprehension of informed consent, pain and anxiety during and after the biopsy procedure, overall satisfaction with KPMP participation, and effect of the study on their lives. The survey was developed in collaboration with the KPMP Community Engagement Committee and the Institute of Translational Health Sciences at the University of Washington. Results: One hundred and eleven participants completed the survey, 23 enrolled for AKI and 88 for CKD. The median age was 61 (interquartile range [IQR], 48–67) years, 43% were women, 28% were Black, and 18% were of Hispanic ethnicity. Survey respondents most commonly joined KPMP to help future patients (59%). The consent form was understood by 99%, and 97% recognized their important role in this study. Pain during the biopsy was reported by 50%, at a median level of 1 (IQR, 0–3) on a 0–10 scale. Anxiety during the biopsy was described by 64% at a median level of 3 (IQR, 1–5) on a 0–10 scale. More than half conveyed that KPMP participation had an effect on their diet, physical activity, and how they think about kidney disease. Conclusions: KPMP survey respondents were most commonly motivated to participate in research protocol kidney biopsies by altruism, with excellent understanding of the informed consent process. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_CJN0000000000000334.mp3 This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_Spanish_CJN00000000.mp3
- 6 September 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (12) , 1616-1625
System-Level Strategies to Improve Home Dialysis
Advocacy and policy change are powerful levers to improve quality of care and better support patients on home dialysis. While the kidney community increasingly recognizes the value of home dialysis as an option for patients who prioritize independence and flexibility, only a minority of patients dialyze at home in the United States. Complex system-level factors have restricted further growth in home dialysis modalities, including limited infrastructure, insufficient staff for patient education and training, patient-specific barriers, and suboptimal physician expertise. In this article, we outline trends in home dialysis use, review our evolving understanding of what constitutes high-quality care for the home dialysis population (as well as how this can be measured), and discuss policy and advocacy efforts that continue to shape the care of US patients and compare them with experiences in other countries. We conclude by discussing future directions for quality and advocacy efforts.
- 6 September 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (12) , 1616-1625
System-Level Strategies to Improve Home Dialysis
Advocacy and policy change are powerful levers to improve quality of care and better support patients on home dialysis. While the kidney community increasingly recognizes the value of home dialysis as an option for patients who prioritize independence and flexibility, only a minority of patients dialyze at home in the United States. Complex system-level factors have restricted further growth in home dialysis modalities, including limited infrastructure, insufficient staff for patient education and training, patient-specific barriers, and suboptimal physician expertise. In this article, we outline trends in home dialysis use, review our evolving understanding of what constitutes high-quality care for the home dialysis population (as well as how this can be measured), and discuss policy and advocacy efforts that continue to shape the care of US patients and compare them with experiences in other countries. We conclude by discussing future directions for quality and advocacy efforts.
- 30 January 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (7) , 961-964
Kidney Transplant Practice in Pandemic Times
An abstract is unavailable. This article is available as a PDF only.
- 30 January 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (7) , 961-964
Kidney Transplant Practice in Pandemic Times
An abstract is unavailable. This article is available as a PDF only.
- 11 October 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (11) , 1953-1954
Patient Perspective on Xenotransplantation
This is an Early Access article. Please select the PDF button, above, to view it.
- 11 October 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (11) , 1953-1954
Patient Perspective on Xenotransplantation
This is an Early Access article. Please select the PDF button, above, to view it.